Biotech

Companies & Industries News

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 02.03.2022.

#AAAAI22
#standwithukraine
#clinicaltrials
#biotech
#genetics
#ukrainewar
#vaccine
#patent
#celltherapy
#biopharma

Companies And Industries

@biospace shared
On Mar 1, 2022
On Sunday, @Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country. #standwithukraine #ukrainewar https://t.co/GeMK1Beos7
Open
Biopharma Takes a Decisive Position on the Russia-Ukraine Conflict

Biopharma Takes a Decisive Position on the Russia-Ukraine Conflict

On Sunday, Boehringer Ingelheim tweeted a message of support for Ukraine, and announced it was standing in solidarity with the embattled Eastern-European country.  

@biospace shared
On Mar 1, 2022
Two new biotech companies launched today: NextRNA to focus on non-coding RNA technology, and Pathalys, with a clinic-ready licensed compound and plans to enter Phase III trials. #clinicaltrials #biotech https://t.co/oaemK7gGIc
Open
New Launches Focus On Non-Coding RNAs and Chronic Kidney Disease

New Launches Focus On Non-Coding RNAs and Chronic Kidney Disease

Two new biotech companies launched today: NextRNA to focus on non-coding RNA technology, and Pathalys, with a clinic-ready licensed compound and plans to enter Phase III trials.

@biospace shared
On Feb 24, 2022
With two proprietary platforms dedicated to developing tRNA-based therapeutics targeting protein dysfunction, hC Bio aims to develop precision protein editing technology to cure genetic diseases. #genetics #pharma https://t.co/2BGkkaUzeK
Open
Takeda-Backed Biotech Grabs $24 Million for tRNA-Based Therapies

Takeda-Backed Biotech Grabs $24 Million for tRNA-Based Therapies

With two proprietary platforms dedicated to developing tRNA-based therapeutics targeting protein dysfunction, hC Bio aims to develop precision protein editing technology to cure genetic ...

@FiercePharma shared
On Feb 28, 2022
.@ArbutusBio and @Genevantsci are taking @moderna_tx to court, claiming the mRNA specialist tread on patents related to the delivery of its COVID-19 vaccine. The lawsuit doesn't ask Moderna to stop making, selling or distributing its shot #patent #vaccine https://t.co/mhYUwvelxg
Open
After raking in billions with its COVID shot, Moderna faces patent infringement suit related to vaccine delivery tech

After raking in billions with its COVID shot, Moderna faces patent infringement suit related to vaccine delivery tech

Last last year, Moderna lost a legal bid to invalidate two Arbutus Biopharma patents tied to the delivery of its COVID-19 vaccine. At the time, it wasn’t so much a question of whether ...

@biospace shared
On Mar 1, 2022
@JNJNewss partner, Legend Biotech, has been awarded @US_FDA approval for its chimeric antigen receptor T-cell (CAR-T) therapy, Carvykti, for the treatment of multiple myeloma. #celltherapy #biopharma https://t.co/DzkQuUcPZ3
Open
J&J, Legend Introduce New CAR-T Therapy to Multiple Myeloma Market

J&J, Legend Introduce New CAR-T Therapy to Multiple Myeloma Market

Johnson & Johnson’s partner, Legend Biotech, has been awarded FDA approval for its chimeric antigen receptor T-cell (CAR-T) therapy, Carvykti, for the treatment of multiple myeloma.

@sanofi shared
On Feb 26, 2022
Positive late-breaking data for our investigational medicine in eosinophilic esophagitis underscore our work with @Regeneron to help people living with this chronic, debilitating disease. Learn more about our research at #AAAAI22: https://t.co/IHwRbb9HCm https://t.co/J14Wjs8QCC
Open
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis

Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis

Read the latest news about our company

@sanofi shared
On Feb 26, 2022
With @Regeneron, we’re presenting late-breaking pivotal data for our investigational medicine in chronic spontaneous urticaria, a debilitating inflammatory skin condition that causes intense itch and hives. Learn more about our research at #AAAAI22: https://t.co/JFFEasEOls https://t.co/XArk14sSkB
Open
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria

Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria

Read the latest news about our company

@BiotechWorld shared
On Mar 1, 2022
IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines https://t.co/E3b1tGagJ8
Open
IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines

IDT Biologika collaborates with Exothera to push forward the scale-up of viral vaccines - read this article along with other careers information, tips and advice on BioSpace

Read more: Companies And Industries
weekly 02.03.2022
View archives
Back to home

Subscribe to Biotech - Companies & Industries.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Companies & Industries.
Privacy Policy

Sign up for the weekly Biotech - Companies & Industries newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Companies & Industries weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy